Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent <i>IDH1</i> mutation.

Blood neoplasia·2026
Same author

Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Leukemia & lymphoma·2026
Same author

Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.

Haematologica·2026
Same author

Matching-Adjusted Indirect Comparison of Olutasidenib and Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Advances in therapy·2026
Same author

Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotype.

Journal of hematopathology·2026
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Apr 17, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.3K

MDS prognostic scoring systems – past, present, and future.

Brian A Jonas1, Peter L Greenberg2

  • 1Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, United States.

Best Practice & Research. Clinical Haematology
|February 10, 2015
PubMed
Summary
This summary is machine-generated.

Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells causing bone marrow failure. New data from flow cytometry and gene mutation analysis are improving prognostic scoring systems for MDS.

Keywords:
cytogeneticsflow cytometrygene expressionmutationsmyelodysplastic syndromesprognosis

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.6K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

875

Related Experiment Videos

Last Updated: Apr 17, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.3K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.6K
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
07:13

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

875

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Myelodysplastic syndromes (MDS) are heterogeneous clonal hematopoietic stem cell disorders.
  • MDS is characterized by ineffective hematopoiesis, leading to bone marrow failure and cytopenias.
  • A significant risk of transformation to acute myeloid leukemia (AML) is a hallmark of MDS.

Purpose of the Study:

  • To review the evolution of prognostic scoring systems in MDS.
  • To highlight the impact of recent advancements on understanding MDS pathogenesis and prognosis.
  • To discuss the need for refining current prognostic models with novel data.

Main Methods:

  • Analysis of clinical characteristics and patient data for prognostic model development.
  • Review of advancements in flow cytometric analysis.
  • Integration of cytogenetics and gene mutation analysis.

Main Results:

  • Existing prognostic models have evolved with improved understanding of MDS.
  • Flow cytometry, cytogenetics, and gene mutation analysis provide new insights into MDS pathogenesis.
  • These novel data sources are crucial for refining prognostic accuracy.

Conclusions:

  • Prognostic scoring systems are essential for guiding clinical decisions in MDS.
  • Recent technological advancements are revolutionizing MDS prognostication.
  • Further refinement of MDS prognostic models using integrated data is necessary.